SS Innovations International (NASDAQ: SSII) has reported significant growth in the global utilization of its SSi Mantra surgical robotic system, with cumulative procedures reaching 14,103 as of Sept. 8, 2026, a 79% increase from 7,885 at the end of 2025. The installed base of systems rose 42% to 238 units from 168, according to the company’s recent update.
The SSi Mantra is now installed in 12 countries, and approximately 1,500 physicians have been trained on the platform, which has been used for more than 170 types of surgical procedures. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the first installation of an SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines.
SS Innovations also highlighted 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of Aug. 31, including a telesurgery spanning more than 13,600 miles between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India.
Looking ahead, the company expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027 and believes European Union CE marking certification can be obtained by year-end 2026. These regulatory milestones are critical for the company’s expansion into major markets and could significantly broaden its addressable customer base.
The growth in procedures and installations underscores the increasing adoption of robotic surgery worldwide, driven by demand for minimally invasive options that can reduce recovery times and improve patient outcomes. For investors, the data points to accelerating commercialization and potential revenue growth as SS Innovations pursues entry into the U.S. and European markets. The company’s focus on affordability and accessibility could also pressure competitors to lower costs, benefiting healthcare providers and patients in emerging economies.
SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. Its product range includes the proprietary SSi Mantra system and the comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
To view the full report, visit https://ibn.fm/DJILj. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer.
Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.
